patientcosts

214 results found.

Top Stocks matching your search for "patient costs"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 15, 2023

$SAVA “Treatment also eased depression and dementi... See more

Feb, 1, 2023

This will bring in billions of revenue and it will... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
TGTX

TG Therapeutics Inc

-19.05%

$18.43 - $14.92

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 13, 2023

The introduction of Briumvi reduces the infusion t... See more

Mar, 8, 2023

In pooled post hoc analyses of ULTIMATE I and II, ... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
BXRX

Baudax Bio Inc

-52.79%

$3.41 - $1.61

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Feb, 13, 2023

“We believe the use of BX1000, combined with our r... See more

Dec, 17, 2022

This could be significantly impactful for patients... See more

SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 15, 2023

$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”

Feb, 1, 2023

This will bring in billions of revenue and it will make the life quality longer for AD patients.

Jan, 29, 2023

This sub-set of patients improved -4.96 mean points on ADAS-Cog from baseline to month 12.

Jan, 18, 2023

CURING LEUKEMIA isn't a fly by night thing with Gamma T Cells and they already have ONE COMPLETE RESPONSE curing someone in Stage 4 nonresponsive to other treatments!

Jan, 11, 2023

$SAVA this is going to be game changer and first drug to give some relief to AD patients … and will make $BIIB poison AD pills an obsolete

Jan, 9, 2023

The high number of the patients that went into CMS (which is 80% complete) is reassuring.

Jan, 6, 2023

but reverses cognitive decline and improves quality of life for the patient AND the FAMILY!

Dec, 30, 2022

but mostly new hope for all the families and patients with AZ.

Dec, 29, 2022

Testing still continues, so in my way of thinking the real-world results in patients must be nothing short of excellent.

TGTX

TG Therapeutics Inc

-19.05%

$18.43 - $14.92

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 13, 2023

The introduction of Briumvi reduces the infusion time to one hour, shortening the patients’ time spent in a clinical setting and allowing them to enhance their quality of life.”

Mar, 8, 2023

In pooled post hoc analyses of ULTIMATE I and II, ublituximab was associated with significant treatment benefit across multiple efficacy measures at Week 96 versus teriflunomide in participants who had not received prior DMT.

Feb, 21, 2023

ATNM just published very good data from their P3 trail which is great news for Acute myeloid leukemia patients.

Feb, 18, 2023

Remember that we are ultimately at the beginning of commercialization and quite possible the safest spot to be with the current facts on our superior Briumvi treatment and best pricing for market share penetration.

Feb, 13, 2023

beyond TG doing well, and us all making a ton of profit, i genuinely hope that this is the answer a lot of MS patients need to help them navigate & improve their illness.

Feb, 3, 2023

Getting the best available treatment for the lowest price is a no brainer.

Jan, 29, 2023

We have built what we consider to be a best-in-class team to support this launch, as well as a robust patient support program designed to aid in accessing BRIUMVI at all points through the treatment journey.

Jan, 21, 2023

They're FDA approved, have the best in class treatment, and is more affordable than the others.

Jan, 10, 2023

Major upgrade for patients and infusion centers -No major health threats like breast cancer or sever liver damage like main competition

Jan, 6, 2023

$TGTX possibly the best therapy available for MS patients that exists today!

BXRX

Baudax Bio Inc

-52.79%

$3.41 - $1.61

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Feb, 13, 2023

“We believe the use of BX1000, combined with our reversal agent, BX3000, could make for precise control of timing under neuromuscular paralysis for surgical patients, which could result in time and cost savings for patients and hospitals alike.

Dec, 17, 2022

This could be significantly impactful for patients, surgeons, and anesthesiologists by enhancing safety, and possibly saving time and reducing costs related to delayed recovery from neuromuscular paralysis following surgical procedures.”

Dec, 9, 2022

It's a miracle drug for patients that suffer with cronic osteoarthritis.

Dec, 9, 2022

It is a game changer for heart patients and is being rapidly adopted by hospitals and doctors.